Dr. Mary S. De Shields
Claim this profileUniversity of Maryland Shore Medical Center at Easton
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
22 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
ER negative
PR negative
2Cancer
HER2 positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Mary S. De Shields is currently running
Chemotherapy + Bevacizumab + Atezolizumab
for Colorectal Cancer
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Recruiting2 awards Phase 31 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
More about Mary S. De Shields
Clinical Trial Related5 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Mary S. De Shields has experience with
- Paclitaxel
- Atezolizumab
- Carboplatin
- Bevacizumab
- Pembrolizumab
- Docetaxel
Breakdown of trials Mary S. De Shields has run
Breast Cancer
Cancer
Adenocarcinoma
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mary S. De Shields specialize in?
Mary S. De Shields focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER negative.
Is Mary S. De Shields currently recruiting for clinical trials?
Yes, Mary S. De Shields is currently recruiting for 2 clinical trials in Easton Maryland. If you're interested in participating, you should apply.
Are there any treatments that Mary S. De Shields has studied deeply?
Yes, Mary S. De Shields has studied treatments such as Paclitaxel, Atezolizumab, Carboplatin.
What is the best way to schedule an appointment with Mary S. De Shields?
Apply for one of the trials that Mary S. De Shields is conducting.
What is the office address of Mary S. De Shields?
The office of Mary S. De Shields is located at: University of Maryland Shore Medical Center at Easton, Easton, Maryland 21601 United States. This is the address for their practice at the University of Maryland Shore Medical Center at Easton.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.